Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Identix (IDNX) -- Ignore unavailable to you. Want to Upgrade?

To: R. Jaynes who wrote (19281)	11/28/2000 11:30:26 AM
From: Spice, J. K.	Read Replies (1) \| Respond to of 26039

Motorola and Compugen Sign Agreement to Design DNA Biochips Date(s): 11/28/2000 9:04:00 AM NORTHBROOK, Ill. & JAMESBURG, N.J.--(BW HealthWire)--Nov. 28, 2000--Motorola Inc. (NYSE:MOT) and Compugen Inc., a wholly-owned subsidiary of Compugen Ltd. (Nasdaq:CGEN), announced today that they have entered into an agreement for the development and manufacture by Motorola Life Sciences of a number of DNA biochips using Compugen's chip design services. This marks the first commercial agreement for Compugen's biochip design services based upon its LEADS platform and proprietary DNA chip design tools. Compugen's LEADS platform and proprietary DNA chip design tools improve scientists' ability to capture both the exact genes of interest, and alternative splice variants of these genes. This feature is designed to capture the biologically active variant of genes, a major advance in the functionality of biochips. Compugen's LEADS technology is an algorithm-driven bioinformatics platform for the analysis and mining of genomic, expressed and protein sequence data. Through this agreement Motorola will utilize Compugen's biochip design services to develop, manufacture and commercialize selected DNA biochips. Financial terms were not disclosed. The commercialization provision offers Motorola's customers access to further related bioinformatic services through a link to LabOnWeb.com, Compugen's life science research engine for genomic, proteomic and transcriptomic analysis. These bioinformatic services will also include exclusive information obtained from Compugen's proprietary databases. "We are very pleased to have been chosen to partner with Motorola, one of the world's leading technology companies, as they create high quality bioarrays to advance healthcare in the post-genomics era," said Eli Mintz, President of Compugen Inc. "Motorola is continuing its commitment to quality and customer service in the life sciences arena, which includes continually building our depth in genomic technologies," said Nicholas Naclerio, vice president and general manager of Motorola's BioChip Systems business. "We believe that Compugen's LEADS technology platform and DNA chip design tools offer significant potential to enhance the utility and applications for DNA biochips. We are very pleased to begin this relationship."